GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » Shares Outstanding (EOP)

Intensity Therapeutics (Intensity Therapeutics) Shares Outstanding (EOP) : 13.71 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Intensity Therapeutics's shares outstanding for the quarter that ended in Mar. 2024 was 13.71 Mil.

Intensity Therapeutics's quarterly shares outstanding increased from Dec. 2023 (13.71 Mil) to Mar. 2024 (13.71 Mil). It means Intensity Therapeutics issued new shares from Dec. 2023 to Mar. 2024 .

Intensity Therapeutics's annual shares outstanding increased from Dec. 2022 (13.10 Mil) to Dec. 2023 (13.71 Mil). It means Intensity Therapeutics issued new shares from Dec. 2022 to Dec. 2023 .


Intensity Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Intensity Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics Shares Outstanding (EOP) Chart

Intensity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
17.59 18.27 13.10 13.10 13.71

Intensity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.10 13.10 13.71 13.71 13.71

Competitive Comparison of Intensity Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Intensity Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intensity Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Intensity Therapeutics's Shares Outstanding (EOP) falls into.



Intensity Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Intensity Therapeutics  (NAS:INTS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Intensity Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Intensity Therapeutics (Intensity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
61 Wilton Road, 3rd Floor, Westport, CT, USA, 06880
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.
Executives
Emer Leahy director 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers officer: Executive VP of CF 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender director, 10 percent owner, officer: President and CEO 765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg director PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski officer: Interim CFO 61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880

Intensity Therapeutics (Intensity Therapeutics) Headlines

From GuruFocus